Abstract:Abstract Funding Acknowledgements Type of funding sources: None. Background A polygenic risk score (PRS) is derived from a genome-wide association study (GWAS) and represents an aggregate of thousands of single-nucleotide polymorphisms (SNPs) that provide a baseline estimate of an individual’s genetic risk for a specific disease or trait at birth. Cardiometabolic disease represents a set of disease processes that historically have disproportionally affected underrepresented racial and minority groups. Furthermore, these groups represent a population generally not well captured by traditional risk scores compared to European cohorts. Since the first GWAS studying myocardial infarction was published, PRSs have increasingly been seen as a promising tool to improve risk stratification of non-European populations. However, how PRSs can be best used in clinical practice remains unclear. Purpose To provide an overview of the PRSs related to cardiometabolic disease, analyze the ancestral diversity of GWAS cohorts, and discuss the evidence supporting their clinical applications. Methods The Preferred Reporting Items For Systematic Reviews and Meta-analysis extension for Scoping Reviews protocol was used to conduct a scoping review of the MEDLINE, EMBASE, and CENTRAL databases. English studies that published a PRS related to atrial fibrillation (AF), cerebrovascular disease (CVD), coronary artery disease (CAD), dyslipidemia, heart failure, heritable cardiomyopathy, hypertension, and type 2 diabetes were reviewed. Results Across the 4,863 studies screened, 82 articles met the inclusion criteria. The most common PRS related to CAD, followed by hypertension and CVD. Limited ancestral diversity was observed as most studies (56) included only individuals of European ancestry. A smaller proportion of studies (16) published PRSs derived in multi-ancestry cohorts. Only ten studies published a PRS derived solely from a sample population of non-European ancestry (Chinese, East Asian, Japanese, and Korean). The predictive performance of most PRSs was similar to or superior to traditional risk factors. More than half of the included studies (42) reported an integrated risk model combining a PRS with traditional risk factors or a clinical risk tool (FRS, PCE, CHADS2). The integrated risk model consistently improved predictive accuracy, but few studies investigated the performance in a non-European population. Conclusion In conclusion, this scoping review is the first of its kind and reports strong evidence for the clinical use of PRSs in AF, CAD, CVD, and hypertension. However, most PRSs are derived in cohorts of European ancestry, which contributes to a lack of PRS transferability across different ancestral groups, likely exacerbating health inequities. Future prospective studies should focus on further establishing the clinical utility of PRSs. Additionally, diversity in future GWAS cohorts is essential to ensure that PRSs reflect the multi-ancestry society at large.

Polygenic risk scores: from research tools to clinical instruments

Implementing polygenic risk scores in the clinic

A perspective on genetic and polygenic risk scores—advances and limitations and overview of associated tools

Taking the risk. A systematic review of ethical reasons and moral arguments in the clinical use of polygenic risk scores

Methodologies underpinning polygenic risk scores estimation: a comprehensive overview

Polygenic Risk Scores: The Next Step for Improved Risk Stratification in Coronary Artery Disease?

Systems biology approaches to utilise polygenic risk scores for chronic diseases

Clinical use of current polygenic risk scores may exacerbate health disparities

Polygenic risk scores in the clinic: new perspectives needed on familiar ethical issues

Current State and Future of Polygenic Risk Scores in Cardiometabolic Disease: A Scoping Review

Applications of Polygenic Risk Scores in Psychiatric Genetics.

Polygenic risk scores for the prediction of cardiometabolic disease

Polygenic Risk Score Implementation into Clinical Practice for Primary Prevention of Cardiometabolic Disease

Polygenic Risk Scores and Genetically Complex Eye Disease

Identifying and characterizing disease subpopulations that most benefit from polygenic risk scores

The personal and clinical utility of polygenic risk scores

The current state and future of cardiometabolic polygenic risk scores in European and non-European population cohorts

Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers

Selection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse US populations

Psychiatric polygenic risk scores: Experience, hope for utility, and concerns among child and adolescent psychiatrists

Polygenic Risk Scores in Alzheimer’s Disease Genetics: Methodology, Applications, Inclusion, and Diversity